3-(2,5-二氟苯基)-7-(1,1-二甲基乙基)-6-[(1-甲基-1H-1,2,4-,三唑-5-基)甲氧基]-1,2,4-4-三唑[4,3-B]哒嗪
中文名称 | 3-(2,5-二氟苯基)-7-(1,1-二甲基乙基)-6-[(1-甲基-1H-1,2,4-,三唑-5-基)甲氧基]-1,2,4-4-三唑[4,3-B]哒嗪 |
---|---|
中文同义词 | 3-(2,5-二氟苯基)-7-(1,1-二甲基乙基)-6-[(1-甲基-1H-1,2,4-,三唑-5-基)甲氧基]-1,2,4-4-三唑[4,3-B]哒嗪;化合物 T19702;化合物 L-838417 |
英文名称 | L-838417 |
英文同义词 | 3-(2,5-Difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4,-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-β]pyridazine;7-(tert-Butyl)-3-(2,5-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine;1,2,4-Triazolo[4,3-b]pyridazine,3-(2,5-difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-;L-838417;3-(2,5-Difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4,-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-b]pyridazine;5-({[7-tert-butyl-3-(2,5-difluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]oxy}methyl)-1-methyl-1,2,4-triazole;L-838417_x000b_ |
CAS号 | 286456-42-6 |
分子式 | C19H19F2N7O |
分子量 | 399.4 |
EINECS号 | |
相关类别 | Heterocycles;Intermediates & Fine Chemicals;Heterocyclic Compounds;Pharmaceuticals |
Mol文件 | 286456-42-6.mol |
结构式 |
3-(2,5-二氟苯基)-7-(1,1-二甲基乙基)-6-[(1-甲基-1H-1,2,4-,三唑-5-基)甲氧基]-1,2,4-4-三唑[4,3-B]哒嗪 性质
熔点 | 196-198°C |
---|---|
密度 | 1.40±0.1 g/cm3(Predicted) |
储存条件 | Store at +4°C |
溶解度 | 二甲基亚砜:≥20mg/mL |
酸度系数(pKa) | 2.13±0.10(Predicted) |
形态 | 粉末 |
颜色 | 白色至类白色 |
Ki: 0.79 nM (α1β3γ2), 0.67 nM (α2β3γ2), 1.67 nM (α3β3γ2), 267 nM (α4β3γ2), 2.25 nM (α5β3γ2) and 2183 nM (α6β3γ2).
L-838417 (1.0 mg/kg) produces anxiolytic effects in adult rat, as indexed by a transformation of social avoidance into preference and an increase in social investigation.
L-838417 (2.0 mg/kg) eliminates social avoidance, but has no anxiolytic effects on social investigation.
L-838417 (0.5 mg/kg) reverses the anxiogenic effects of prior stress regardless of age, but with doses ≥ 1 mg/kg decreases social investigation, an effect possibly due in part to locomotor-impairing effects of this compound.
Animal Model: | Male and female adolescent and adult Sprague–Dawley rats. |
Dosage: | 0, 0.5, 1.0, 2.0, or 4.0 mg/kg. |
Administration: | IP. |
Result: |
Adolescents required a higher dose (2 mg/kg) to attenuate their social avoidance.
The lowest dose of 0.5 mg/kg was sufficient to reverse the anxiogenic effects of repeated restraint as reflected by a significant increase in the coefficient relative to vehicle-treated animals. |
安全信息
WGK Germany | 3 |
---|